Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Seeking success with SITESEEKER
February 2020
SHARING OPTIONS:

CAMBRIDGE, U.K.—PhoreMost Limited and Boehringer Ingelheim have teamed up in a multi-project drug discovery collaboration under which PhoreMost will apply its SITESEEKER next-generation phenotypic screening platform to identify novel targets in disease-relevant pathways selected by Boehringer Ingelheim. Though specific financial details were not released, the agreement stipulates that PhoreMost will receive an upfront payment, research funding and downstream success-based milestone payments. Boehringer Ingelheim will validate and characterize any identified targets.
 
Dr. Chris Torrance, CEO of PhoreMost, said: “We are delighted that Boehringer Ingelheim has chosen to work with PhoreMost to enhance its drug discovery pipeline with attractive biological starting points. The collaboration is further recognition of the ability of PROTEINi and SITESEEKER to identify novel targets, and we look forward to working with the Boehringer Ingelheim team on these projects.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.